NEURL4 Activators
Chemical activators of NEURL4 can influence its activity through various cellular mechanisms that impinge on the endosomal sorting complex required for transport (ESCRT) machinery, with which NEURL4 is associated. The activation of the EGF receptor by EGF leads to increased endocytosis, a process that is critically dependent on the ESCRT machinery. NEURL4, as a component of this machinery, could be functionally activated due to the augmented load of endocytic vesicles that need to be sorted. Similarly, Phorbol 12-myristate 13-acetate (PMA) engages protein kinase C (PKC), which modulates endocytic trafficking. The activation of PKC can create a cellular environment that necessitates the heightened activity of the ESCRT machinery, thereby leading to the functional activation of NEURL4 to meet the increased demands of vesicle trafficking and signal transduction.
Chloroquine and Monensin, by disrupting endosomal acidification, and Bafilomycin A1, by inhibiting V-ATPase, can indirectly influence the ESCRT machinery. This influence can place additional functional demands on NEURL4 to compensate for the altered trafficking and degradation processes within the endosome. Compounds like U18666A, which induces intracellular cholesterol accumulation, can also affect endosome and lysosome function. This may lead to a scenario where the activity of NEURL4 is upregulated to deal with the perturbed lipid homeostasis and maintain cellular trafficking functions. Similarly, ML-9, as a kinase inhibitor, may impact cytoskeletal dynamics and indirectly require the activation of NEURL4 for the maintenance of vesicle formation and trafficking. Other chemicals that affect endocytic pathways, such as Pitstop 2 and Dynasore, could also necessitate the activation of NEURL4 as a compensatory mechanism for the inhibition of clathrin-mediated and dynamin-mediated endocytosis, respectively. Lastly, compounds like Wortmannin, YM201636, and Vacuolin-1 that modulate endosomal sorting or morphology could lead to cellular conditions that require the functional activation of NEURL4 for the regulation and adaptation of the endocytic and lysosomal pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC) which can modulate endocytic trafficking. PKC activation may increase the demand on the ESCRT machinery, potentially requiring the functional activation of NEURL4 for efficient trafficking and signal transduction. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine disrupts endosomal acidification, which can affect endosomal sorting and potentially increase the functional requirements for NEURL4 in the ESCRT pathway to compensate for altered trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that alters endosomal pH, potentially modulating the ESCRT machinery and indirectly requiring the functional activation of NEURL4 for the maintenance of endocytic sorting processes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
By inhibiting V-ATPase, Bafilomycin A1 prevents endosomal acidification, which could impact the ESCRT machinery. This might increase the functional demand on NEURL4 to compensate for impaired receptor degradation or recycling. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A induces intracellular cholesterol accumulation, affecting endosome and lysosome function. This could necessitate enhanced activity of the ESCRT machinery and potentially increase the functional activation of NEURL4. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML-9 is a kinase inhibitor that can influence various signaling pathways, including those involving cytoskeletal dynamics. This could indirectly affect the ESCRT machinery and require the functional activation of NEURL4 for vesicle formation and trafficking. | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 inhibits clathrin-mediated endocytosis, which can lead to compensatory upregulation of other endocytic pathways, potentially increasing the requirement for NEURL4 activity in the ESCRT machinery. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore is a GTPase inhibitor that blocks dynamin-mediated endocytosis. This disruption could indirectly necessitate increased functional activation of NEURL4 as part of the cellular response to maintain endocytic processing. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase inhibitor that can affect endosomal sorting. By modulating this pathway, there could be an indirect demand on NEURL4 for the regulation of the ESCRT machinery involved in endocytic trafficking. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $213.00 | 6 | |
YM201636 inhibits PIKfyve, affecting phosphatidylinositol 3-phosphate levels on endosomes. This could indirectly necessitate the functional activation of NEURL4 for appropriate endosomal sorting and vesicle formation. | ||||||